We aim to share scientific findings through a comprehensive publication process entailing:
Rapamycin Press, the new publishing division of Impact Journals, LLC, will continue to bring you Aging, Oncotarget, Oncoscience and Genes & Cancer. We host a team of experts in scholarly publishing and provide unrivaled services, resulting in the success of our journals.
Aging, launched in 2009, publishes papers of general interest and biological significance in all fields of aging research, including topics beyond traditional gerontology.
Oncotarget, launched in 2010, is a twice-weekly, traditional, peer-reviewed, multidisciplinary journal with open-access, covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology, including gerotarget/aging, pathology (beyond oncology), immunology and microbiology, autophagy and cell death, chromosomes, and more.
Oncoscience, launched in 2014, covers the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. Oncoscience also has a special mission: Freeing researchers in oncology from publication costs. It is free for the readers and the authors.
Genes & Cancer, formerly a SAGE publication, was acquired in 2014 and covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, including their roles in signal transduction and the mechanisms by which their expression and function are altered during tumor development.